.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Fuji
Cantor Fitzgerald
McKinsey
Teva
Dow
Moodys
Cipla
Accenture
Farmers Insurance

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Method for predicting the response to treatment with an HER2-blocking agent
Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.
Inventor(s): Pages; Gilles (Monaco, MC)
Assignee: UNIVERSITE DE NICE SOPHIA ANTIPOLIS (Nice, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR)
Application Number:14/125,155
Patent Claims:1. An in vitro or ex vivo method for determining the response of a patient to treatment with trastuzumab and treating a patient determined to be responsive to treatment with trastuzumab, said method comprising the steps of: i) identifying (a) or (b) at a rs3746083 polymorphic site at position 367 in a nucleotide sequence of SEQ ID NO: 3 coding for a tristetraprolin protein in a biological sample from said patient: (a) heterozygosity (T/C) or homozygosity (T/T) indicating that said patient is determined to be not responsive to treatment with trastuzumab; (b) homozygosity (C/C) indicating that said patient is determined to be responsive to the treatment with trastuzumab; ii) determining the level of the tristetraprolin protein in a biological sample from said patient and comparing it with at least one reference value, wherein the level of the tristetraprolin protein in the biological sample is greater than or equal to a reference value, the patient is predicted to be responsive to the treatment with trastuzumab; and iii) administering trastuzumab to said patient being determined to be responsive to treatment with trastuzumab, wherein said patient is suffering from HER2-positive breast cancer.

2. An in vitro or ex vivo method of prognosis or diagnosis of HER2-positive breast cancer in a patient and treating a patient determined to have said cancer, comprising: i) identifying (a) or (b) at a rs3746083 polymorphic site at position 367 in a nucleotide sequence of SEQ ID NO: 3 coding for a tristetraprolin protein in a biological sample from said patient; (a) heterozygosity (T/C) or homozygosity (T/T) indicating that said patient is determined to be not responsive to treatment with trastuzumab, (b) homozygosity (C/C) indicating that said patient is determined to be responsive to the treatment with trastuzumab, and ii) administering trastuzumab to said patient being determined to have HER2-positive breast cancer.

3. The method according to claim 2, wherein the cancer is HER2-positive breast cancer with a poor prognosis.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France11 55128Jun 10, 2011
PCT Information
PCT FiledJune 07, 2012PCT Application Number:PCT/EP2012/060807
PCT Publication Date:December 13, 2012PCT Publication Number: WO2012/168370

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe UNIVERSITE DE NICE SOPHIA ANTIPOLIS (Nice, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) Pages; Gilles (Monaco, MC) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Canada2838767Dec 13, 2012
European Patent Office2718462Apr 16, 2014
France2976294Dec 14, 2012
Japan2014519330Aug 14, 2014
United States of America2014377252Dec 25, 2014
World Intellectual Property Organization (WIPO)2012168370Dec 13, 2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Chubb
US Army
Merck
Citi
Queensland Health
Healthtrust
Farmers Insurance
Cipla
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot